Supplemental File 1 from Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

Summary of Assessment of Ki-67 Staining Problems. Supplementary Table 1: Summary of Values, Changes, and Statistical Results for Ki-67 Assessments. Supplementary Table 2: Summary of Analyses of Different Subsets of Subjects.</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in anthropomorphic variables. Supplementary Table 3: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 4: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 5: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in fatty acid content in all five compartments. Supplementary Table 3. Change in anthropomorphic variables. Supplementary Table 4: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 5: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 6: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplementary Figures and Tables from Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer

Supplementary Figures and Tables</p